Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 44.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 792,499 shares of the company's stock after purchasing an additional 245,168 shares during the quarter. Fisher Asset Management LLC owned 0.55% of Denali Therapeutics worth $16,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Quest Partners LLC bought a new stake in shares of Denali Therapeutics in the third quarter worth approximately $73,000. Assetmark Inc. boosted its holdings in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after buying an additional 580 shares during the period. KBC Group NV grew its position in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after purchasing an additional 2,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after buying an additional 920 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Denali Therapeutics by 128.8% during the 4th quarter. SG Americas Securities LLC now owns 11,003 shares of the company's stock valued at $224,000 after purchasing an additional 6,195 shares during the last quarter. 92.92% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNLI. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. The Goldman Sachs Group decreased their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. HC Wainwright lifted their price target on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. B. Riley restated a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday. Finally, William Blair reiterated an "outperform" rating on shares of Denali Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $37.27.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded up $0.42 during trading hours on Friday, hitting $16.69. The company had a trading volume of 1,620,939 shares, compared to its average volume of 1,004,688. The firm has a market cap of $2.40 billion, a P/E ratio of -6.05 and a beta of 1.43. The company has a 50-day moving average price of $20.88 and a two-hundred day moving average price of $24.35. Denali Therapeutics Inc. has a 1 year low of $14.01 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Transactions at Denali Therapeutics

In other news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 3,080 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares of the company's stock, valued at $2,257,778.16. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.